6628 fundamentals

Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company, which engages in discovery, research, development, and manufacturing of differentiated antibody therapies in therapeutic areas with high unmet medical needs. It focuses on oncology, nephrology, and bone diseases. Its products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm also provides contract development and manufacturing organization (CDMO) services, mainly including process development services, GMP production services, cell line development services, sample testing services, formula optimization services and drug formation research. The company was founded on August 20, 2010 and is headquartered in Suzhou, China.